Gour Medical SA entered into a definitive worldwide license agreement to acquire Worldwide Rights to a dual orexin receptor antagonist from Actelion Pharmaceuticals Ltd on March 10, 2015. Under the terms of the agreement, Actelion will receive an upfront payment and will be eligible to receive further payments subject to potential development and regulatory milestones, as well as royalties on sales if the compound is commercialized.

Gour Medical SA cancelled its agreement to acquire Worldwide Rights to a dual orexin receptor antagonist from Actelion Pharmaceuticals Ltd on March 10, 2016.